The University of Pennsylvania has taken a novel approach to ensure that women with suspicious adnexal lesions are referred ...

Clinicians should adopt a risk-based, rather than biopsy-first, approach to encourage biopsy acceptance and improve early ...

A clinician nudge for referral to a gynecologic oncologist at the time of suspected ovarian cancer diagnosis improved ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...

today announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC in an oral presentation at the Society of Gynecologic Oncology (SGO) 2025 ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...

Black women tend to get more aggressive uterine cancers than White women. But this is only part of the story, investigators and patients say.

The cancer antigen (CA)-125 test may miss ovarian cancer in some Black and Native American patients, delaying their treatment ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to ...

today announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC in an oral presentation at the Society of Gynecologic Oncology (SGO ...